It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Psoriasis is a chronic inflammatory skin disease with autoimmune pathogenic characteristics
and is caused by chronic inflammation, which results in uncontrolled keratinocyte growth …

Molecular recognition is a useful property shared by various molecules, such as antibodies,
aptamers and molecularly imprinted polymers (MIPs). It allows these molecules to be …

TNF and IL-17 are two cytokines that drive dysregulated keratinocyte activity, and their
targeting is highly efficacious in patients with psoriasis, but whether these molecules act with …

Background BE SURE 1-year results demonstrated the superior efficacy of bimekizumab
compared with adalimumab with no unexpected safety findings. Objectives To provide …

Background Discontinuation of biologics is common among patients with psoriasis due to
treatment failure or adverse events. To achieve improvements in disease management …

Abstract Background Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab
biosimilar with similar efficacy and comparable safety and immunogenicity to reference …

Background Confirmatory data on the long-term effectiveness and safety of ixekizumab in
psoriatic patients from real-world studies are needed. Objectives The primary aim was to …

Simple Summary The major histocompatibility complex class II-associated peptide
proteomics assay is widely used during preclinical immunogenicity risk assessments to …

Introduction Significant advances in psoriasis treatment have taken place since the
introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics …